Clearview Cancer Center

Quick Links:

Clearview News Wire

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.



Prostate biopsy can cause urinary, erectile problems

August 31, 2010

Last Updated: 2010-08-30 14:52:31 -0400 (Reuters Health)

By Amy Norton

NEW YORK (Reuters Health) - Biopsies taken to diagnose prostate cancer commonly cause temporary erectile dysfunction and, in some cases, lingering urinary problems, according to a new study.

The findings, reported in the Journal of Urology, highlight the fact that even the tests for diagnosing prostate cancer can have side effects.

And men who are undergoing prostate biopsies -- as well as those considering prostate cancer screening -- should be aware of those risks, experts say.

This is especially important for men facing the prospect of multiple biopsies, since the risk of side effects appears to be related to the number of needle sticks used.

For the study, German researchers followed 198 men who had been randomly assigned to undergo one of three forms of biopsy to check for suspected prostate cancer: a standard biopsy, where a needle was used to take no more than 10 tissue samples; a 10-sample biopsy along with the use of a periprostatic nerve block to lessen any pain from the procedure; or a "saturation" biopsy, where 20 tissue samples were taken.

Saturation biopsies may be done in some cases where the doctor suspects a man has a particularly elevated risk of having cancer -- such as a man who has had a negative biopsy in the past yet has persistently suspicious findings on PSA screening tests. Taking more tissue samples during the biopsy should increase the chances of finding any tumor.

But all those needle sticks may come at a cost, the study found.

Men who underwent saturation biopsies had the highest risk of developing lingering problems with urination, such as straining to pass urine and frequent nighttime trips to the bathroom.

Of that group, 10 percent reported severe symptoms before the biopsy; that figure increased to 18 percent one week after the test, and to 29 percent 12 weeks afterward.

Men who'd had a standard biopsy showed an increase in urinary symptoms only in the first week. The percentage reporting moderate symptoms increased from roughly 32 percent to 39 percent, and the proportion with severe symptoms rose from 18 percent to 20.5 percent.

Among men who'd had a biopsy with nerve block, just 0.6 percent reported severe urinary symptoms before the test. That rose to 8 percent one week afterward, and to almost 17 percent by week 12 -- though that latter finding was not statistically significant, which means it could have been due to chance.

When it came to erectile function, men in all three biopsy groups had more problems one week after the test. The side effect did, however, gradually decrease over time.

Among men in both the standard biopsy and saturation-biopsy groups, just over half reported severe erectile dysfunction one week after the test -- up from around one-quarter before. In the nerve-block group, that rate rose from 11 percent to 39 percent.

By week 12, the men's rates of erectile problems had declined to close to their baseline levels.

The findings are "not unexpected," said Dr. Paul Schellhammer, a urologist at Sentara Health System/Eastern Virginia Medical School in Norfolk who was not involved in the research.

However, he noted in an interview, there has been little study into the urinary and erectile side effects of prostate biopsies.

"This study begins to define the risks," said Schellhammer, who has studied the effects of prostate cancer treatment on men's sexual and urinary function.

Men facing repeat biopsies over time -- whatever the type of biopsy -- should be particularly aware of the chances for side effects, Schellhammer told Reuters Health, since it appears that the greater the number of needle-sticks into the prostate, the greater the odds of lingering urinary problems.

It is not clear from this study exactly why men undergoing saturation biopsy had a greater risk of longer term urinary symptoms, according to lead researcher Dr. Tobias Klein of Marienhospital Herne in Germany.

But it is possible, he told Reuters Health in an email, that damage to the "neurovascular bundle" -- a complex of nerves and blood vessels close to the prostate -- plays a role.

The fact that prostate biopsies carry some risks -- which, besides the ones seen in this study, include more-immediate problems like bleeding and infection -- also has implications for men considering prostate cancer screening, according to Schellhammer.

Routine screening with PSA testing is controversial. The tests measure concentrations of prostate-specific antigen, a protein produced by the prostate gland whose blood levels generally rise when a prostate tumor is present; however, a relatively high PSA does not necessarily mean cancer, and a biopsy must be done to confirm. And those biopsies often turn out to be negative.

In the current study, 40 percent of the men were found to have cancer after their prostate biopsy.

Much of the concern about PSA testing revolves around the fact that prostate tumors are often slow-growing, and screening may result in many men being treated for cancers that would never have caused them problems. So those treatments -- with their risks of side effects like erectile dysfunction and urinary incontinence -- can do more harm than good for some men.

But men should also be aware, Schellhammer said, that prostate biopsies can have side effects as well, and that can be considered when they are making decisions on PSA screening.

He added that the findings are also relevant to men diagnosed with prostate cancer who choose "active surveillance" -- where the doctor does not immediately treat the cancer, but instead monitors its progression. That surveillance, Schellhammer noted, might include yearly biopsies.

SOURCE: http://link.reuters.com/wew28n Journal of Urology, online August 19, 2010.

Other Articles:

February 3, 2012
Senators urge Komen to reconsider funding decision
February 1, 2012
Eating fish tied to lower risk of colon polyps
January 31, 2012
Kids seek tans, use less sunscreen as they Age
January 18, 2012
FDA approves BTG's drug for cancer toxicity
January 5, 2012
Argentina's Fernandez undergoes cancer surgery
December 20, 2011
Vitamin D has mixed effects on cancer, broken bones
December 13, 2011
Memory issues after cancer may not be due to chemo
December 8, 2011
Quicker radiation therapy doubles mastectomy risk
December 7, 2011
Prostate cancer hormonal therapy cuts deaths: report
November 17, 2011
More fruit tied to lower risk of uterine fibroids
November 15, 2011
Brain scan study finds evidence of 'chemo brain'
November 9, 2011
No link between selenium, lower lung cancer risk
November 8, 2011
Singer Andy Williams reveals he has cancer
November 7, 2011
More evidence obesity tied to colon cancer
November 4, 2011
More evidence obesity tied to colon cancer
October 31, 2011
Heavy drinking tied to higher stomach cancer risk
October 28, 2011
Heavy drinking tied to higher stomach cancer risk
October 27, 2011
Doctors split on Avastin for breast cancer: survey
October 21, 2011
More breast cancer diagnosed in women with diabetes
October 20, 2011
US health panel cautious on HPV screening vs Pap
October 19, 2011
Girls' HPV vaccination rates falling short
October 18, 2011
Should your hairdresser screen you for skin cancer?
October 14, 2011
Flaxseed may not cool hot flashes
October 12, 2011
Vitamin E tied to higher risk of prostate cancer
October 10, 2011
Antioxidants tied to mixed effects in breast cancer
September 28, 2011
Diabetes again linked to colon cancer risk
September 28, 2011
Chemotherapy appears safe in pregnancy: study
September 20, 2011
Gene therapy shows promise in reducing HIV
September 15, 2011
CORRECTION: Bachmann HPV vaccine comments 'toxic': US doctors
September 14, 2011
IUDs almost halve risk of cervical cancer: study
September 13, 2011
More painkiller use linked to kidney cancer
September 7, 2011
Zimbabwe's Mugabe has prostate cancer: WikiLeaks
September 6, 2011
Folate tied to lower colon cancer risk
September 6, 2011
Vitamin D levels tied to colon cancer risk
August 30, 2011
New breast cancer gene may help predict risk
August 26, 2011
Cancer patients like Jobs face risks from treatment
August 25, 2011
Ovarian cysts may not lead to cancer: study
August 22, 2011
FDA approves Seattle Genetics cancer drug
August 18, 2011
REFILE: FDA approves Roche skin cancer drug Zelboraf
August 17, 2011
Not enough evidence for bladder cancer screening
View All Cancer News